Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis

Published:2023-02 Issue: Volume:26 Page:100261
ISSN:2666-6022
Container-title:American Heart Journal Plus: Cardiology Research and Practice
language:en
Short-container-title:American Heart Journal Plus: Cardiology Research and Practice

Author:

Rivera Frederick Berro,Tang Vincent Anthony S.,De Luna Deogracias Villa,Lerma Edgar V.,Vijayaraghavan Krishnaswami,Kazory Amir,Shah Nilay S.,Volgman Annabelle Santos

Publisher

Elsevier BV

Subject

General Medicine

Reference34 articles.

1. Heart failure in women;Taylor;Curr. Heart Fail. Rep.,2015

2. Heart disease and stroke Statistics-2021 update: a report from the American Heart Association;Virani;Circulation,2021

3. Heart failure in women;Bozkurt;Methodist Debakey Cardiovasc. J.,2017

4. Timely and individualized heart failure management: need for implementation into the new guidelines;Abdin;Clin. Res. Cardiol.,2021

5. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N. Engl. J. Med.,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes;ESC Heart Failure;2024-09-10

2. Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk;Diabetes, Obesity and Metabolism;2024-06-10

3. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials;American Journal of Preventive Cardiology;2024-06

4. Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes;The American Journal of Cardiology;2024-05

5. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-15